Be a Pet Health Hero
Help advance a new era of veterinary care by participating in a Gallant clinical trial
Our investigational regenerative therapies are part of a growing movement to restore health at the source—and clinical studies are how we get there.
Why Stem Cells?
Gallant’s uterine-derived stem cell therapies are built on mesenchymal stromal cells (MSCs) sourced from healthy, FDA-qualified donors. These stem cells are being studied for their ability to target sites of immune dysregulation, modulate inflammatory responses, and restore normal biological function. Unlike traditional treatments that only manage symptoms, stem cells offer a disease-modifying approach—one that holds potential to improve quality of life by addressing the root cause of chronic and immune-mediated diseases.
Explore our Clinical Trials
Gallant is evaluating investigational stem cell therapies intended to address the underlying biology of disease. Each clinical trial is fully funded by Gallant and conducted by trained veterinary professionals at participating clinics.
Clinical Trial participants receive:
- Access to investigational therapy
- Study-related veterinary care (e.g., physical exams, blood work, urinalysis)
- The chance to be a Pet Health Hero by helping Gallant demonstrate the safety and effectiveness of our products for FDA approval
Explore the studies below to see what’s enrolling now—and whether one may be a fit for your clinic or your pet.
Feline Chronic Gingivostomatitis (FCGS), also known as gingivostomatitis or caudal stomatitis, is a painful and debilitating inflammatory condition affecting the mouth. It can occur in up to 10% of cats, affecting millions of cats in the United States alone.
FCGS causes painful sores in the mouth, which may lead to the following symptoms:
- Reduced appetite
- Weight loss
- Drooling
- Excessive licking
- Reluctance to groom
- Increased vocalization
- Bleeding gums
Treatment for FCGS typically involves removal of some or all of the teeth and daily oral medications to reduce inflammation and pain. Thirty to fifty percent of cats do not improve substantially after these treatments and continue to suffer from chronic pain, a condition known as refractory FCGS.
In refractory FCGS, pain medications and anti-inflammatories may have little effect, and cats may be euthanized due to their poor quality of life. Fortunately, stem cell therapy may offer new hope for cats who have exhausted other treatment options.
This study is evaluating stem cell therapy for refractory FCGS in cats who have not responded to tooth extraction and medical management.
Feline Chronic Kidney Disease (CKD) affects 40% of cats over 10 years of age and 80% of cats over 15 years of age. CKD is the leading cause of death in cats over 5 years of age. CKD is caused by inflammation and scarring in the kidney that progresses over time. Reduced kidney function results in accumulation of waste products that can cause cats to feel ill. Complications such as high blood pressure, low red blood cell count, and protein loss are common and often associated with disease progression and poor quality of life.
Clinical signs of CKD include:
- Weight loss
- Increased drinking and urination
- Poor body condition
- Reduced appetite
- Bad breath
Common treatment for CKD involves supportive care, such as fluid therapy and special diets, to stabilize kidney function and treat metabolic complications. However, these treatments do not address the underlying progressive disease, and the daily administration of medications can be stressful for cats and their caregivers.
This study is evaluating stem cell therapy for chronic kidney disease in cats.
Feline Osteoarthritis (OA) is a progressive joint disease characterized by joint inflammation and cartilage breakdown. OA affects 90% of older cats resulting in increased pain and decreased mobility which negatively impact physical appearance, energy and vitality, mood, sociability, and physical and mental wellbeing.
Clinical signs of Feline OA include:
- Reduced willingness to jump or reduced height of jumping
- Difficulty using stairs
- Slowing down
- Behavior changes including irritability and resenting being touched
- Reduced ability to use the litterbox
- Lameness is more rare
Common treatments for feline OA involve giving anti-inflammatories, pain medications and joint supplements, but these treatments do not address the underlying progressive disease and daily medication administration can be stressful for cats and their caregivers.
This study is evaluating stem cell therapy for cats with feline osteoarthritis.
Canine Osteoarthritis (OA) is a progressive joint affecting over 20% of dogs more than 1 year of age and up to 80% of dogs more than 8 years of age. OA is not a “normal” part of aging; inflammation plays a role in the onset and progression of disease which results in cartilage damage, scar tissue formation, and bony changes within the joint.
Clinical signs of Canine OA include:
- Limping/abnormal gait
- Stiffness
- Decreased activity/reluctance to move
- Difficulty getting up or lying down
- Slowing down
- Behavior changes including irritability and resenting being touched
- Licking/chewing at painful joints
- Muscle wasting
Common treatments for canine OA involve giving anti-inflammatories, pain medications and joint supplements, but these treatments do not address the underlying progressive disease and daily medication administration can be burdensome and costly for caregivers.
This study is evaluating stem cell therapy in dogs with osteoarthritis.
Atopic Dermatitis (AD) is an allergic inflammatory skin disease affecting 10-15% of dogs. The immune system of dogs with AD is in an overactive/pro-inflammatory state, causing inflammation in the skin. Many dogs with AD are worse seasonally when they are more exposed to a certain allergen.
Clinical signs of AD include:
- Itching
- Red, inflamed skin
- Ear infections
- Licking/chewing paws
- Hair loss
- Thickened skin
- Secondary skin infections
Common treatment for AD involves giving medications to reduce skin inflammation and control itch, but these treatments do not address the underlying progressive disease and daily medication administration can be burdensome and costly for caregivers.
This study is evaluating stem cell associated for dogs with canine atopic dermatitis.
Find a Clinic Near You
Clinical trials are enrolling at veterinary clinics across the U.S. Use the map below to search by condition and ZIP code.
If you find a participating site—or even if you don’t—we’re here to help.
Get in touch and we’ll share more information and connect you with a clinic if one is enrolling near you.
Questions About Clinical Trials?
Our FAQ covers what participation looks like, how investigational therapies are evaluated, and what to expect along the way.
Still need answers? We’re here to help.
Clinical sites receive comprehensive support from our clinical research team throughout the process that includes remote and on-site training, educational materials, and case recruitment materials. Please contact us at info@www.gallant.com and we’ll be happy to put you in touch with our clinical trials team to discuss more details.
Please contact us at info@www.gallant.com and we’ll be happy to put you in touch with our clinical trials team to discuss whether your clinic meets the site and staff requirements to become a clinical trial site.
Clinical trials typically involve minimal or no cost. Specifics vary per program. Please contact us at info@www.gallant.com and we’ll be happy to with our clinical trials team to discuss specifics.
The speed at which clinical signs improve after stem cell therapy is variable and depends on individual factors and the underlying disease state. Improvement in clinical signs can be seen in some animals as quickly as 24 hours after treatment. Resolution of lesions often takes longer as tissue repair takes time. Whereas some animals improve dramatically after one treatment, others require multiple treatments to see significant improvement.
